Deutsche Bank AG Invests $1.90 Million in Urogen Pharma $URGN

Deutsche Bank AG bought a new position in Urogen Pharma (NASDAQ:URGN) during the 2nd quarter, Holdings Channel reports. The institutional investor bought 51,550 shares of the company’s stock, valued at approximately $1,897,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Urogen Pharma by 7.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after acquiring an additional 1,653 shares during the last quarter. Persistent Asset Partners Ltd acquired a new position in shares of Urogen Pharma in the 2nd quarter valued at about $66,000. Main Street Financial Solutions LLC lifted its stake in shares of Urogen Pharma by 8.2% in the 2nd quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock valued at $356,000 after purchasing an additional 1,968 shares in the last quarter. Barclays PLC grew its holdings in shares of Urogen Pharma by 3.8% during the 4th quarter. Barclays PLC now owns 57,744 shares of the company’s stock worth $1,352,000 after purchasing an additional 2,125 shares during the period. Finally, Osaic Holdings Inc. grew its holdings in shares of Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after purchasing an additional 3,070 shares during the period. Institutional investors and hedge funds own 91.29% of the company’s stock.

Insider Activity at Urogen Pharma

In other news, insider Mark Schoenberg sold 60,677 shares of the business’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $47.05, for a total transaction of $2,854,852.85. Following the transaction, the insider directly owned 59,086 shares of the company’s stock, valued at approximately $2,779,996.30. The trade was a 50.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 85,899 shares of company stock worth $3,747,513 over the last 90 days. Insiders own 4.80% of the company’s stock.

Urogen Pharma Stock Performance

URGN stock opened at $43.62 on Friday. The firm has a market cap of $2.13 billion, a P/E ratio of -22.03 and a beta of 1.57. Urogen Pharma has a 1 year low of $15.86 and a 1 year high of $50.81. The stock has a 50-day simple moving average of $41.81 and a 200-day simple moving average of $29.95.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The business had revenue of $72.46 million during the quarter, compared to analysts’ expectations of $63.55 million. On average, equities research analysts predict that Urogen Pharma will post -0.2 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on URGN. UBS Group restated a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. The Goldman Sachs Group reiterated a “neutral” rating and set a $44.00 price objective on shares of Urogen Pharma in a research note on Wednesday, July 15th. HC Wainwright increased their price objective on shares of Urogen Pharma from $45.00 to $75.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research note on Friday, July 17th. Finally, Oppenheimer lifted their target price on shares of Urogen Pharma from $40.00 to $50.00 and gave the company an “outperform” rating in a report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $50.38.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.